跳至主要内容
临床试验/ACTRN12626000948392
ACTRN12626000948392进行中(未招募)不适用

A surveillance study extending community pharmacy influenza-like illness surveillance to adults aged 18 years and older

Medical Research Institute of New Zealand0 个研究点目标入组 200 人开始时间: 2026年8月10日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Other
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 No limit(—)
性别
All

入选标准

  • Aged 18 year and over
  • Able and willing to give informed consent to participate
  • confirmed symptoms of influenza-like-illness (ILI), per the sentinel general respiratory surveillance programme:
  • a. History of fever (subjective or measured) or a measured fever of ³38°C AND
  • b. Cough, AND
  • c. Acute onset in the past 10 days

排除标准

  • Nasopharyngeal or sinus condition such as a deviated septum or chronic rhinitis, which the investigator considers could impair ability to swab
  • Recent facial trauma (30 days)
  • Recent surgery to the facial region or upper airways, or clinical procedure such as bronchoscopy involving the nasal passages that could impair the ability to swab or any other reason, they are unable to have a nasopharyngeal swab taken
  • Recent surgery to the sinus/nasal passages (90days)
  • Chronic nasal blockage
  • Participation in the Sentinel General Practice Respiratory Virus Surveillance programme in the previous four weeks
  • Participation in this current study within the previous four weeks
  • Self-reported confirmed current COVID-19 infection
  • The pharmacist, GP, or other health advisor such as Healthline advises participant to be seen at their GP or afterhours service for urgent review and treatment

研究者

相似试验

进行中(未招募)
不适用
A community pharmacy based investigation in the self-medication areaEfficacy and safety of Sinutab® [Paracetamol (500mg) and Pseudoephedrine (30mg)] on subjects with nasal congestion accompanied by headache in the setting of a common coldThe medical rationale = to investigate this combination drug in the symptomatic relief of common cold with nasal symptoms. The reduction of symptom severity may allow subjects receiving active medication to return to work or school earlier than those receiving placebo. To study the drug in it’s ‘natural environment’, community pharmacists will function as local investigators. They will include subjects with early (= 48 hours) cold symptoms of blocked nose with headache.
EUCTR2006-000058-35-BEPfizer Consumer Healthcare Comm. VA/SCA
进行中(未招募)
不适用
A community pharmacy based investigation in the self-medication areaEfficacy and safety of Sinutab® (Paracetamol (500mg)/Pseudoephedrine (30mg)) on subjects with nasal congestion accompanied by headache and/or fever in the setting of a common coldMedical rationale= Investigation of combination drug Sinutab in symptomatic relief of common cold with nasal symptoms. Community pharmacists are considered as local investigators including subjects with early (= 48 hours) cold symptoms of blocked nose with headache and/or fever.
EUCTR2004-001637-41-BEPfizer Consumer Healthcare cva/sca
尚未招募
不适用
PREDICT-DM: Community Pharmacy-Based Point-of-Care Testing for Undiagnosed T2DMPrediabetic StatePrediabetes / Type 2 DiabetesDiabetes Mellitus, Type 2T2DM
NCT07795918Universiti Sains Malaysia480
尚未招募
不适用
Impact of pharmacist provided health education on ASHA workers knowledge and practices
CTRI/2026/03/106079vikrama simha reddy60
尚未招募
4 期
Awareness on proper use of antibiotics among higher secondary school students in Udupi taluk
CTRI/2023/12/060877Manipal College of Pharmaceutical Sciences, Manipal263
An surveillance study extending community pharmacy... | 临床试验